Abraham MD, Cohen PDA, Jan van Til R, Langemeijer MPS. (1998). Licit and illicit drug use in Amsterdam. Developments in drug use 1987-1997. CEDRO, Amsterdam, p56.

Battaglia G, Yeh SY, O’Hearn E, Molliver ME, Kuhar MJ, DeSouza MB. (1987). 3,4-methylenedioxymethamphetamine and 3,4-methylinedioxyamphetamine destroy serotonergic terminals in the rat brain: quantification of neurodegeneration by measurements of [3H]paroxetine labelled serotonin uptake sites. J Pharmacol Exp Ther 242:911-916.

Battaglia G, Yeh SY, DeSouza MB. (1988). MDMA induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurones. Pharmacol Biochem Behav 29:269-274.

Bolla KI, McCann UD, Ricaurte GA. (1998). Memory impairment in abstinent MDMA (“ecstasy”) users. Neurology 51:1532-1537.

Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE. (2000). Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res Neuroimaging 98:15-28.

Cooper JR, Bloom FE, Roth RH (eds). The biochemical basis of neuropharmacology. Oxford university press. 6th ed (1991).Oxford, UK.

Curran HV, Travill RA. (1997). Mood and cognitive effects of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy): weekend “high” followed by midweek low. Addiction 92:821-831.

Davison D, Parrott AC. (1997). Ecstasy (MDMA) in recreational users: self reported psychological and physiological effects. Hum Psychopharmacol Clin Exp 12:221-226.

Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R. (1998). Serotonergic function after 3,4-methylenedioxymethamphetamine (ecstasy) in humans. Int Clin Psychopharmacol 13:1-9.

Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M. (2000). Long lasting effects of 3,4-methylenedioxymethamphetamine (ecstasy) on serotonergic function in humans. Biol Psychiatry 47:127-136.

Goldblum P. (1996). Better than well. The economist 6.4.96 p8.

Hatzidimitriou G, McCann UD, Ricaurte GA. (1999). Altered serotonin innervation patterns in the forebrain of monkeys treated with 3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19:5096-5107.

Iravani MM, Asari D, Patel J, Wieczorek WJ, Kruk ZL. (2000). Direct effects of 3,4-methylenedioxymethamphetamine (MDMA). On serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia pars reticula, and the dorsal raphe nucleus slices. Synapse 36:275-285.

Jansen K. (1997). Adverse psychological effects, In: Saunders N (ed) Ecstasy reconsidered. Saunders, London.

Johnston LD, O’Mally PM, Bachman JG. (2000). Monitoring the future national survey results on adolescent drug use: overview of the key findings, 1999. National institute on drug abuse, Rockville.

Liechti ME, Baumann C, Gamma A, Vollenweider FX. (2000). Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) are attenuated by the serotonin uptake inhibitor Citalopram. Neuropsychopharmacology 22:513-521.

McCann UD, Ridenour A, Shaham Y, Ricaurte GA. (1994). Serotonin neurotoxicity after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy): a controlled study in humans. Neuropsychopharmacology 10:129-138.

McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. (1998). Positron emission tomographic evidence of toxic effect of MDMA (ecstasy) on brain serotonin neruones in human beings. Lancet 352:1433-1437.

McCann UD, Mertl M, Eligulashvili V, Ricaurte GA. (1999). Cognitive performance in 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) users: a controlled study. Psychopharmacology 143:417-425.

Mintzer MD. (1999). Parkinsonism after taking ecstasy. NEJM 340:1443

Morgan MJ. (2000). Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152:230-48.

O’Shea E, Granados R, Esteban B, Colado MI, Green AR. (1998). The relationship between the degree of neurodegeneration in the rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (ecstasy). Neuropharmacology 37:919-926.

O’Shea E, Esteban B, Camerero J, Green AR, Colado MI. (2001). Effect of GBR12909 and Fluoxitine on the acute and long term changes induced by MDMA on the 5-HT and dopamine concentrations in the mouse brain. Neuropharmacology 40:65-74.

Peroutka SJ, Pascoe N, Faull KF. (1987). Monoamine metabolites in the cerebrospinal fluid of recreational users of 3,4-methylenedioxymethamphetamine (MDMA ecstasy). Res Commun Substance abuse 8:125-138.

Peroutka SJ, Newman H, Harris H. (1988). Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1:273-277.

Price LH, Ricaurte GA, Krystal GH, Heninger GR. (1989). Neuroendocrine and mood responses to L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users: preliminary observations. Arch Gen Psychiatry 46:20-22.

Rattray M. (1991). Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. Essays in biochemistry 26:77-87.

Reneman L, Booij J, Schmand B, Brink W, Gunning B. (2000). Memory disturbances in ecstasy users are correlated with an altered serotonin neurotransmission. Psychopharmacology 148:322-324.

Ricaurte GA, DeLanney LE, Irwin I, Langston JW. (1988). Toxic effects of MDMA on central serotonergic neurones in the primate: importance of route and frequency of drug administration. Brain Res 446:165-168.

Ricaurte GA, Katz JL, Martello MB. (1992). Lasting effects of 3,4-methylenedioxymethamphetamine on central serotonergic neurons in non-human primates. J Pharmacol Exp Ther 261:616-622.

Schifano F, Magni G. (1994). MDMA (ecstasy) abuse: psychopathological features and craving for chocolate: a case series. Biol Psychiatry 36:763-767.

Schmidt CJ.(1987). Neurotoxicity of the psychadelic amphetamine methylenedioxymethamphetamine. J Pharmacol Exp Ther 240:240-247.

Schultz SK, Andreasen NC. (1999). Schizophrenia. Lancet 353:1425-1430.

Semple DM, Ebmeier KP, Glabus MF, O’Carroll RE, Johnstone EC.(1999). Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (ecstasy) users. Br J Psychiatry 175:63-69.

Topp L, Hando J, Dillon P, Roche A, Solowij N. (1999). Ecstasy use in Australia: patterns of use and associated harm. Drug alcohol depend 55:105-115.

Tucker GT, Rostami A. (2000). Principles of interspecies scaling, in: Pharmacokinetics: an introductory course. Sheffield UK.

Yamamoto BK, Spanos LJ, (1988). The acute effects of methylenedioxymethamphetamine on dopamine release in the awake behaving rat. Eur J Pharmacol 148:195-204.